Background-␣ 2A -Adrenoceptors (␣ 2A -ARs) have important roles in sympathetic cardiovascular regulation. Variants of ADRA2A affect gene transcription and expression and are associated with insulin release and risk for type 2 diabetes. We examined whether ADRA2A variants are also associated with cardiovascular responses to the selective ␣ 2 -ARagonist dexmedetomidine. Methods and Results-Seventy-three healthy subjects participated in a placebo-controlled, single-blind study. After 3 infusions of placebo, subjects received 3 incremental infusions of dexmedetomidine (cumulative dose, 0.4 g/kg). Primary outcomes were changes in systolic blood pressure (SBP) and plasma norepinephrine concentrations, measured as difference of the area-under-the-curve during placebo and dexmedetomidine infusions (⌬AUC). We used multiple linear regression analysis to examine the associations between 9 ADRA2A tagging variants and 5 inferred haplotypes and ⌬AUC after adjustment for covariates. Homozygous carriers of rs553668 and the corresponding haplotype 4, previously associated with increased ␣ 2A -AR expression, had a 2.2-fold greater decrease in AUC SBP after dexmedetomidine (adjusted Pϭ0.006); similarly, the maximum decrease in SBP was 24.7Ϯ8.1 mm Hg compared with 13.6Ϯ5.9 mm Hg in carriers of the wild-type allele (Pϭ0.007). Carriers of haplotype 3, previously associated with reduced ␣ 2A -AR expression, had a 44% smaller decrease in AUC SBP (Pϭ0.013). Haplotype information significantly improved the model predicting the decrease in SBP (PϽ0.001). There were similar but nonsignificant trends for diastolic blood pressure and heart rate. Genotypes were not significantly associated with norepinephrine responses. 
A lpha 2A -Adrenoceptors (␣ 2A -ARs) are important regulators of sympathetic tone through central and peripheral (presynaptic) sympathetic inhibition. They are also directly involved in several homeostatic functions, including contraction and relaxation of vascular smooth muscle, control of vigilance, anxiety and stress-related behaviors, pain perception, platelet aggregation, lipolysis, and insulin release. Genetically engineered mice that do not express the ␣ 2A -AR gene (ADRA2A) have a hyperadrenergic phenotype with increased blood pressure, heart rate, and plasma norepinephrine concentrations and develop cardiac hypertrophy and heart failure. [1] [2] [3] [4] Moreover, ADRA2A knockout mice do not decrease blood pressure in response to an ␣ 2 -AR-agonist such as clonidine. 1 
Clinical Perspective on p 187
We and others have systematically defined genetic variation and the haplotype structure of ADRA2A. 5, 6 Some of the variants identified have distinct functional effects on receptor expression or function in vitro. 6 -8 However, studies to define the functional significance of ADRA2A genetic variation in cardiovascular regulation in vivo have yielded inconsistent results. Some studies have found associations between ADRA2A variants and hypertension, 9 -11 whereas others, including 2 genome-wide association studies, have not. [12] [13] [14] [15] Blood pressure is regulated by many factors and mechanisms, and the contributions of single genetic variants to blood pressure regulation may be difficult to detect in population-based studies, where many confounding variables remain uncontrolled. A more sensitive approach to defining the functional effects of genetic variants in membrane-bound receptors is the administration of a pharmacological agonist or antagonist in a controlled experimental setting. 16 -18 Indeed, Sober et al 11 recently hypothesized that functional ADRA2A variants could affect the pharmacological responses to ␣ 2 -AR agonists such as clonidine.
Thus, we examined the hypothesis that ADRA2A variants affect cardiovascular responses to ␣ 2 -AR-agonists by administering dexmedetomidine, a selective ␣ 2 -AR-agonist, to healthy volunteers in a highly controlled setting.
Methods Subjects
The Institutional Review Board of Vanderbilt University Medical Center approved the study protocol, and subjects gave written informed consent. Details of the study methods and subjects have been published previously. 19, 20 In brief, we studied unrelated healthy American black and white subjects, aged 18 to 45 years, without clinically significant abnormal findings on medical history, physical examination, or routine laboratory testing. For 5 days before the study, subjects were on an alcohol-and caffeine-free diet (providing 150 mmol of sodium, 70 mmol of potassium, and 600 mmol of calcium daily). All subjects were free of medications and dietary supplements for at least 2 weeks.
Study Procedure
The study was placebo-controlled, single-masked, and was performed at the Vanderbilt University Clinical Research Center. After an overnight fast, intravenous cannulas were placed in antecubital veins bilaterally, one for blood collection and the other for drug infusion. After a 30-minute supine resting period, blood pressure (BP) and heart rate were obtained from the left brachial artery with a semiautomated device (Dinamap MPS; GE Medical Systems, Waukesha, WI), and a blood sample was taken for DNA extraction and measurement of baseline plasma catecholamine concentrations. All heart rate and BP measurements were performed twice and averaged for analysis. After baseline measures, 6 infusions (each infusion lasted 10 minutes and was followed by a 20-minute observation period) were administered ( Figure S1 , online-only Data Supplement). Placebo (normal saline) was infused during cycles 1 to 3 and dexmedetomidine (Precedex, Abbott Laboratories, Abbott Park, IL) at doses of 0.1, 0.15, and 0.15 g/kg body weight, respectively, during cycles 4 to 6 (cumulative dose, 0.4 g/kg). Ten minutes after each infusion, heart rate and BP were measured and a blood sample was drawn for measurement of plasma catecholamine and dexmedetomidine concentrations.
Genotyping
We genotyped 9 ADRA2A tag single nucleotide polymorphisms (tagSNPs) representing common genetic variations in black and white Americans 5 (Table S1 , online-only Data Supplement). The selection of tagSNPs was based on our previous study of 135 demographically similar black and white residents of Nashville, in whom we sequenced ADRA2A (including approximately 2.2 kb of 5Ј-flanking and 0.1 kb of 3Ј-flanking regions) and found 41 SNPs, among which we selected 9 tagSNPs by LD-based binning (binning criterion, r 2 Ն0.4) and prevalence criteria (MAF Ն5%) that optimally captured genetic variability of ADRA2A. 5 We genotyped the 9 tagSNPs by allelic discrimination with TaqMan 5Ј-nuclease assays 21 on an ABI 7900 HT real-time PCR system (Applied Biosystems, Foster City, CA) using validated TaqMan probes. For genotyping quality control, we included 6 samples with known genotypes previously determined by direct sequencing, 5 and all control samples had concordant genotypes.
Haplotype Assignment
Haplotypes were inferred from the 9 tagSNPs using an expectationmaximization algorithm implemented in the software Powermarker. 5 Because subtypes of haplotypes 4 and 5 were expected to be infrequent, we grouped these subtypes into haplotype families for analysis as previously defined. 5 The variant rs553668 was a tagSNPs for haplotype 4, and rs553668 genotype groups therefore comprised the same patients as corresponding HT4 haplotype groups. Only haplotypes that could be inferred with Ն85% probability were assigned; haplotypes with Ͻ85% probability were handled as missing data.
Plasma Catecholamine Determination
Blood was collected into cooled heparinized tubes that were immediately placed on ice until centrifuged at 4°C for 10 minutes at 3000 rpm. Plasma was separated and stored at Ϫ20°C in tubes containing 40 L of reduced glutathione (6%) until assayed. Norepinephrine and epinephrine concentrations were measured by high-performance liquid chromatography using electrochemical detection with dihydroxybenzylamine as internal standard. 22 
Plasma Dexmedetomidine Determination
Plasma dexmedetomidine concentrations were determined by reversed-phase high-performance liquid chromatography with tandem mass spectrometric detection 23 (PE Sciex API4000, PE Sciex, Foster City, CA) as previously described. 23, 24 
Data and Statistical Analysis
Data are expressed as means and standard deviations (SD) or 95% confidence intervals (CI). Genotype distribution was tested for deviation from Hardy-Weinberg equilibrium with the use of a 2 test with 1 degree of freedom. To generate a summary variable representing the overall response, we plotted outcomes (systolic and diastolic BP, heart rate, and plasma catecholamine concentrations) against time for each subject and determined the area under the curve (AUC) for the 1.5-hour periods of placebo (AUC PLAC ) and dexmedetomidine infusions (AUC Dex ), respectively, by the trapezoidal rule, assuming linear changes between the measurements. AUC data were normally distributed, and dexmedetomidine responses were assessed as the difference between AUC Dex and AUC PLAC for each outcome variable by paired t test. In a sensitivity analysis, we also assessed the decrease in the outcome measure between the last placebo infusion and the last dexmedetomidine infusion. Because low doses of dexmedetomidine preferentially reduce systolic blood pressure and plasma norepinephrine concentrations, 5,24 -26 changes in these variables were the primary outcomes, and changes in heart rate and plasma epinephrine concentrations were secondary outcomes. For single-marker analysis of the nine tagSNPs, we used 1-way ANOVA to compare outcomes by number of variant alleles. When there were 2 or fewer subjects homozygous for the variant allele, we grouped them with heterozygous carriers for statistical analysis. To adjust for potential covariates (age, sex, race, plasma dexmedetomidine concentration, body mass index [BMI] , and AUC PLAC for the corresponding outcome), we performed linear regression analyses, assuming an additive mode of inheritance for the SNP. For each of the 5 haplotypes, we created biallelic genotypes by treating the haplotype as a variant allele and grouping the other haplotypes together as the other allele, and repeated the above analyses. In addition, we also performed multiple linear regression analyses including all covariates and all 5 haplotypes with additive haplotypic effects. All tests were 2-tailed. In these exploratory analyses, we did not adjust for multiple comparisons, and probability values of Ͻ0.05 were considered statistically significant. Analyses were performed with the statistical software packages R (www.r-project.org) and SPSS (SPSS v.15.0, SPSS Inc, Chicago, IL).
Results

Subjects
We studied 73 healthy subjects; their demographic characteristics and baseline measures are shown in Table 1 .
ADRA2A Genotypes and Haplotypes
Genotypes of the 9 ADRA2A variants could be determined in 94.5% to 100% of the subjects (mean call rate, 98.2%) and are shown in Table S1 (online-only Data Supplement). Minor allele frequencies were in the expected range in both ethnic groups. 6, 27 All genotypes conformed to Hardy-Weinberg equilibrium in each ethnic group (all PϾ0.10). Haplotype families could be assigned to 99.3% of haplotypes with Ͼ85% probability, and the haplotype distribution was in the expected range (Table S2 , online-only Data Supplement). 5 
Determinants of Outcomes at Baseline and During Placebo
Men (ϩ8.9 mm Hg; 95% CI, 5.3 to 12.4 mm Hg; PϽ0.001), black ethnicity (ϩ4.6 mm Hg; 95% CI, 1.1 to 8.1 mm Hg; Pϭ0.010), and a higher BMI (per kg/m 2 unit, ϩ0.6 mm Hg; 95% CI, 0.05 to 1.1 mm Hg; Pϭ0.033) were individually associated with higher systolic BP at baseline, and similarly, during placebo infusions. After adjustment for these covariates, none of the ADRA2A tagSNPs or haplotypes was associated with systolic BP or any of the other outcomes (diastolic BP, plasma norepinephrine and epinephrine concentrations, and heart rate) at baseline or during the placebo infusions (all PϾ0.07).
ADRA2A Variants and Systolic BP Responses to Dexmedetomidine
During the dexmedetomidine infusions, the AUC for all outcome measures decreased significantly compared with that during placebo infusions (Table 2 ; all PՅ0.028; Figure  S2 , online-only Data Supplement). For the primary outcome, systolic BP, a higher AUC SBP during placebo was associated with a greater decrease in AUC SBP during dexmedetomidine (Pϭ0.007), but other covariates (age, sex, race, BMI, dexmedetomidine concentration) did not affect the reduction. Table 3 shows ⌬AUC SBP in genotype groups by single marker analysis assuming an additive model of inheritance. Three subjects homozygous for rs553668 had a 115% (2.2-fold; 95% CI, 1.5 to 2.8-fold; Pϭ0.001) greater decrease in AUC SBP than carriers of 1 of more copies of the major allele, and the difference remained significant after adjustment for covariates (9.6 mm Hg; 95% CI, 2.8 to 16.4 mm Hg*h; Pϭ0.006; Figure 1) . A similar trend for rs2484516 did not reach statistical significance (adjusted Pϭ0.07; Table 3 ). Table 4 shows ⌬AUC SBP by haplotypes in single haplotype analyses. Homozygous or heterozygous carriers of haplotype 3 (HT3) had a 44% smaller reduction in AUC SBP (ie, a smaller hypotensive response; adjusted Pϭ0.008), whereas the 3 subjects with 2 copies of HT4 (already defined above by the rs553668 variant) had 2.2-fold greater reductions in AUC SBP (ie, a larger hypotensive response) than carriers of 1 or no copy (adjusted Pϭ0.006; Figure 1 ). When analyzing races separately in a sensitivity analysis, white and black homozygotes for rs553668/HT4 had a similarly larger ⌬AUC SBP compared with the other genotypes (2.3-fold and 2.1-fold for whites and blacks, respectively); however, genotype differences were statistically significant only in whites (unadjusted Pϭ0.003), probably reflecting the small sample size for black homozygotes (nϭ1).
Adding all ADRA2A haplotypes into a model predicting ⌬AUC SBP that included all other covariates improved the model significantly, increasing the coefficient of determination R 2 (the percent of the variability of ⌬AUC SBP explained by the model) from 19.2% to 32.2% (PϽ0.001). In this model, HT3 carrier status was associated with a smaller (Pϭ0.013) and HT4 with a larger hypotensive SBP response (Pϭ0.047) to dexmedetomidine (Table S3 , online-only Data Supplement). When HT4 was modeled as a recessive trait, taking into account the post hoc observation that only homozygous HT4 carriers had greater hypotensive responses, the association between HT4 and ⌬AUC SBP was stronger (Pϭ0.007).
In a sensitivity analysis, as an additional assessment of responses to dexmedetomidine, we analyzed the reduction in systolic BP between the last placebo infusion and the last dexmedetomidine infusions (⌬SBP). In this analysis, haplotype 4 was also associated with a greater hypotensive response, and haplotype 3 with a smaller response ( Figure  2) , with a magnitude similar to that observed with the summary measure ⌬AUC SBP . Carriers of HT3, compared with noncarriers, had a 39% (0.61-fold) smaller hypotensive response (⌬SBPϭ8.8Ϯ6.5 mm Hg and 14.5Ϯ6.1 mm Hg, respectively; Pϭ0.015), and subjects homozygous for HT4 had an 82% (1.8-fold) greater hypotensive response (⌬SBPϭ24.7Ϯ8.1 mm Hg compared with 13.6Ϯ5.9 mm Hg; Pϭ0.007; Figure 2 ) compared with carriers of other haplotypes.
For the second main outcome, change in plasma norepinephrine concentrations between placebo and dexmedetomidine infusions, ⌬AUC NE was not affected by ADRA2A 
ADRA2A Variants and Secondary Outcomes
For secondary outcomes, in single marker analyses, the same markers associated with a greater hypotensive response for SBP (rs553668 and HT4) were also associated with a greater decrease in diastolic BP (⌬AUC DBP ; Pϭ0.040) and heart rate (⌬AUC HR ; Pϭ0.033; Figure 1 
Discussion
In this study, we systematically defined the effects of common ADRA2A variants on cardiovascular responses to the selective ␣ 2 -AR agonist, dexmedetomidine. Our main findings are that ADRA2A variants previously associated with changes in ␣ 2A -AR expression contribute to the interindividual variability in BP and heart rate responses to dexmedetomidine, with particular genotypes or haplotypes being associated with approximately 40% smaller and 100% greater hypotensive responses, respectively. The 3Ј-UTR SNP rs553668 (GϾA), formerly identified as the DraI restriction fragment length polymorphism, defines the haplotype 4 family and has a minor allele frequency of approximately 15% in white and 20% to 30% in black populations. 5, 6 Some earlier studies reported a higher prevalence of the rs553668 variant allele in various populations with high blood pressure but several recent studies, including 2 large genome-wide analyses, did not confirm these findings. The molecular mechanisms for potential phenotypic effects of this variant have been partially elucidated.
In cell lines transfected with different ADRA2A haplotypes, 3 of 4 haplotypes containing the variant rs553668 allele were associated with increased ␣ 2A -AR mRNA transcription. 6 The rs553668 variant also resulted in increased ␣ 2A -AR expression on pancreatic islet cell membranes and thus decreased insulin secretion; moreover, it is associated with an increased prevalence of type 2 diabetes mellitus. 8 Thus, the observation that rs553668/HT4 are associated with increased cell surface ␣ 2A -AR expression is biologically concordant with our finding of increased responses to the ␣ 2 -AR agonist dexmedetomidine. Interestingly, beyond SBP, reductions in the secondary outcomes diastolic BP and heart rate were also more pronounced in subjects carrying this variant.
ADRA2A haplotype 3 is characterized by a minor allele at a single SNP (rs1800544) in the absence of other SNPs. This AUC indicates area under the curve; SBP, systolic blood pressure; NE, norepinephrine; HT, haplotype, and n.a., not represented in cohort.
Decrease of systolic BP and NE was assessed as difference between the area under the curve for the respective variables between placebo infusions and dexmedetomidine infusions (⌬AUCSBP and ⌬AUCNE, respectively).
Uncorrected P values are from multiple linear regression analysis assuming an additive model of inheritance. Adjusted P values are after adjustment for the covariates AUCSBP or AUCNE during placebo, respectively, dexmedetomidine plasma concentrations, age, sex, race, and body mass index. Except placebo AUCSBP and placebo AUCNE, respectively (PϽ0.021 in all analyses), no other covariate was significantly associated with the outcomes. *For statistical analysis, the single subject homozygous for HT3 was grouped with the 7 heterozygous carriers.
haplotype occurs in 8% to 11% of black Americans but has not been described in white populations. 5, 6 In the present study, carriers of haplotype 3 had significantly smaller hypotensive responses to dexmedetomidine. Interestingly, in a study with haplotype-transfected cell lines, Small et al 6 found this same haplotype (designated as haplotype 1 in their nomenclature) to have the lowest transcription (about 60% of the ␣ 2A -mRNA of the wild-type haplotype) and receptor expression (about 20% of the wild-type haplotype) compared with other haplotypes. Thus, the smaller hypotensive response to dexmedetomidine that we observed in carriers of haplotype 3 is concordant with its in vitro effects of lower ␣ 2A -AR expression. We did not find an association between ADRA2A variants and the reduction in plasma norepinephrine concentrations after dexmedetomidine. Possible explanations include the lack of statistical power in view of our sample size and the fact that in non-steady-state conditions, such as occur after dexmedetomidine administration, plasma norepinephrine concentrations are not an ideal measure of sympathetic activity. Norepinephrine spillover studies would be a more precise way of assessing sympathetic activity, but because they involve administration of radiolabeled norepinephrine to measure clearance, they are technically challenging and not feasible for larger study cohorts.
Our findings have several implications. First, variants and haplotypes predicted to affect ␣ 2A -AR expression have functional effects on cardiovascular regulation in vivo, concordant with previous findings in vitro. Because the effect size was considerable (with mean differences in hypotensive responses ranging from 0.6-fold to 2.2-fold for particular ADRA2A haplotypes), ADRA2A genetic variation may contribute to interindividual differences in BP regulation, especially after physiological (stress-induced) or pharmacological activation (by ␣ 2 -AR agonists such as clonidine and dexmedetomidine). Clinically, ␣ 2 -agonists are used to date primarily as antihypertensive agents (clonidine) or for sedation and anesthesia during surgery or in the intensive care setting (dexmedetomidine), and predicting interindividual variability in hypotensive BP response (either as therapeutic goal or adverse drug effect) could be of significant clinical importance. Additionally, because ADRA2A variants have in vivo functional effects on cardiovascular outcomes, other ␣ 2A -AR-mediated outcomes such as platelet function, metabolic regulation, or various central nervous system functions may be similarly affected. In fact, with respect to the ␣ 2A -AR-mediated inhibition of insulin secretion from islet cells, a recent study confirmed the association of ADRA2A rs553668 with impaired insulin secretion and type 2 diabetes mellitus, and a meta-analysis of genome-wide association studies (GWAS) identified a strong association of rs10885122, a variant approximately 200 kb downstream of ADRA2A, with higher fasting glucose. 8, 28 In addition, a recent GWAS identified 1 SNP each in whites and blacks downstream ADRA2A (about 63 to 70 kb) to be associated with decreased epinephrineinduced platelet aggregation. 29 In contrast, despite the role of ␣ 2A -ARs in spinal and central nervous system pain processing, in a previous study we did not find any association between ADRA2A variants and pain perception in an experimental pain model. 20 Our study had several strengths and limitations. We used the highly selective ␣ 2 -AR agonist dexmedetomidine to avoid cardiovascular effects mediated by ␣ 1 -ARs, as occurs with mixed agonists, for example, clonidine. To account for interindividual differences in dexmedetomidine pharmacokinetics, we measured plasma dexmedetomidine concentrations and adjusted for these in our analyses. We studied healthy subjects in a highly controlled study setting to avoid the confounding effects of environmental factors, disease, and concomitant drugs. This design increased our ability to isolate the functional effects of genetic ADRA2A variants; however, our findings cannot necessarily be extrapolated to patients with hypertension or other diseases. Other limitations include the small sample size, resulting in some small genotype groups and thus wide confidence intervals around the estimates of effect sizes. Thus, our findings are preliminary and require validation in larger, clinical cohorts. ADRA2A variants and haplotype structure vary between whites and blacks, 5,6,29 but our cohort was underpowered for meaningful separate analyses by race. Nevertheless, the trend toward increased BP reduction in subjects homozygous for rs553668 was similar in magnitude in both races. Indeed, consistency of an association between a variant and a given outcome across multiple ethnic groups with differences in genetic diversity and haplotype structure can be helpful in differentiating truly causal variants from those merely associated with such causative variants by linkage disequilibrium. 30 Additionally, the tagSNPs we used represent well the genetic variability of ADRA2A and its 3Ј-flanking region (approximately 2.2 kb) in our study population, but we did not cover more distant intergenic variants. This may be significant in view of the recently reported association of reduced epinephrine-induced platelet aggregation with 2 more distant variants (rs4311994 in whites and rs869244 in blacks) approximately 63 to 70 kb downstream ADRA2A, 29 and another report of a distant downstream variant (202 kb; rs10885122) associated with increased fasting glucose. 28 It is unclear whether these functional associations with distant downstream variants represent linkage disequilibrium with causal variants in closer proximity to or within ADRA2A or long-range regulatory elements. 29 Using data available on Hapmap, we found that none of these variants is in significant linkage disequilibrium with rs553668, the variant associated with increased dexmedetomidine responsiveness in our study (all r 2 Յ0.125 for both Caucasians with European ancestry and blacks from Yoruba, Nigeria). Thus, multiple variants within and around ADRA2A may be associated with diverse ␣ 2A -ARmediated responses, possibly reflecting tissue-specific effects of specific genetic variants or study-related methodological differences.
In conclusion, this translational study provides evidence that genetic variants in ADRA2A are associated with different blood pressure responses to the selective ␣ 2 -selective agonist dexmedetomidine. Variants or haplotypes previously linked with greater or lesser gene transcription/expression were associated with approximately 100% greater and 40% lesser responses to the drug, respectively. Future studies of these variants in other cardiovascular settings, for example, stress responses, and other physiological functions mediated by the ␣ 2A -AR will be of interest.
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